These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38737553)

  • 1. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.
    Thaneetrakool T; Aroonparkmongkol S; Numsriskulrat N; Supornsilchai V; Wacharasindhu S; Srilanchakon K
    Front Endocrinol (Lausanne); 2024; 15():1390674. PubMed ID: 38737553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
    Wiromrat P; Panamonta O
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months.
    Vatopoulou A; Roos E; Daniilidis A; Dinas K
    Gynecol Endocrinol; 2020 Dec; 36(12):1124-1126. PubMed ID: 32484003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty.
    Mul D; de Muinck Keizer-Schrama SM; Oostdijk W; Drop SL
    Horm Res; 1999 Dec; 51(6):270-6. PubMed ID: 10640887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
    Lee HS; Yoon JS; Park KJ; Hwang JS
    PLoS One; 2018; 13(8):e0201906. PubMed ID: 30133462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).
    Borges Mde F; Franciscon Pde M; Cambraia TC; Oliveira DM; Ferreira BP; Resende EA; Palhares HM
    Arch Endocrinol Metab; 2015 Dec; 59(6):515-22. PubMed ID: 26421668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty.
    Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL
    J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
    Cohen D; Janfaza M; Klein KO
    J Pediatr Endocrinol Metab; 2009 Jul; 22(7):629-34. PubMed ID: 19774844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.